TORONTO, ONTARIO Sept. 26, 2017 - Interface Biologics, a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI's Endexo® technology.

JLabs is offering a slew of events for October ranging from pitching to partnering. Click the link below to see the full offerings.

Information and registration

MARKHAM, ON, Sept. 20, 2017 Edesa Biotech Inc., a clinical-stage private company announced today the completion of a $7 million Series A financing.  The internationally syndicated investment was led by Lumira Capital and included participation from Pharmascience Inc., Inveready Technology Investment Group and a number of Canadian family offices.

The MedTech Conference will be held in Toronto, Ontario, in 2020 from October 5-7, marking the first time that the conference will be held outside of the U.S.

IndieBio is the world’s largest biotechnology accelerator, and Proteorex presented as part of the Batch 5 Cohort. The company is is developing small molecule drugs for challenging targets implicated in diseases with the highest unmet need. 

The presentation was delivered in San Francisco this September 14th by Dr. Marc Adler, Co-Founder and Technology Director of Proteorex.

MaRS Innovation and Evotec AG today announced the launch of “LAB150”.  This transformational Toronto-based partnership will give Canada access to the world-class infrastructure and drug discovery expertise of Evotec, and pair it with cutting-edge drug discovery projects emerging from the 15 Member institutions of MaRS Innovation.

Lab150 is a joint effort by MaRS Innovation and Evotec AG selection and acceleration of early-stage drug discovery projects originating from leading academic institutions and teaching hospitals in Toronto (Canada)

Biotechnology Focus, in collaboration with Stratford Managers Corporation, wants to learn more about employee perception of their workplace.

Please complete the survey in its entirety before September 22nd. The responses will be included in in a sector report that will be featured in the October/November issue of Biotechnology Focus.

To start the Survey click here

Program Overview

Seed funding for novel, high-risk, high-reward translational research to accelerate the development of safe and effective treatments for neurodegenerative diseases of aging. Funding up to $200,000 over up to 18 months

Letter of Intent Deadline: December 4, 2017 at 2pm EST

Program Information Session: October 10, 2017 at 1pm EDT (Register here)

Application Form

Montreal, September 12, 2017 – Twenty-two members of Anges Québec, Anges Québec Capital, and Aligo Innovation today announced a major joint investment in Ovensa, the company behind an innovative technology enabling the targeted delivery of therapeutic molecules.

Synaptive Medical Inc.’s brain simulator training kit, which simulates the features of a living brain to allow users to practice procedures such as stitching a blood vessel, has received an honorable mention in the health category of Fast Company’s 2017 Innovation by Design Awards.

The 3rd annual INTERFACE HEALTH CHALLENGE X 2017 (#IHCX2017 competition seeks to find the world’s most innovative digital health start-ups.

This year CAAP companies KomodoOpenLab and KE2 Technologies have made it to the Top 10, guaranteeing a cash prize and putting them in contention for the $40K 1st Prize.

CAAP company SensOR Medical's ForceFilm technology, a thin add-on for minimally invasive surgical (MIS) instruments that provides surgeons with a digital sense of touch to help improve surgical safety, was selected as the Canadian James Dyson Award winner. SensOR will receive $3,400 toward ForceFilm’s development.

SensOR will now enter the International competition, where it will go up against other national winners for the ultimate $50,000 prize.

Pre-CAAP Company Trexo Robotics is featured in the September 6 edition of the Daily Mail UK.

MedStack and Zensurance recently announced a partnership that will bring competitive cyber-liability insurance packages to MedStack customers. Digital health companies on MedStack's platform meet the highest levels of security and stability, qualifying them for exclusive cybersecurity insurance packages from Zensurance.

Therapure Biopharma Inc. today announced that a joint venture between 3SBio Inc., a leading global biotechnology company, and CPE Funds has entered into an agreement to acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market for US$290 million, subject to certain adjustments.

Pre-CAAP company Iris Technologies has developed screen technology to allow people suffering from post-concussion symptoms to read with less pain/fatigue. This news story on CTV features the results of a study from Toronto Western Hospital.